BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax is a potent and selective BCL‐2 inhibitor that has demonstrated high objective response rates as a monotherapy in patients with CLL, a B‐cell malignancy that possesses a strong dependence on BCL‐2 for survival.